Skip to main content

Svoronos Dawn's Form 4 filing

Xenon Pharmaceuticals Inc.XENE · filed Aug 24, 2023

Accession no.
0000950170-23-044403
Filed
Aug 24, 2023
Trade date
Aug 24, 2023
Filing delay
Same day
Rule 10b5-1 plan
Not checked

This filing lists 1 non-derivative transaction. Open-market sales total $967.5K. It was filed on the trade date.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Svoronos DawnCIK 0001574579Director

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Aug 24, 2023Common SharesSSaleDisposed−25,000$38.70F1−$967,50025,000Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F1

The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $38.70 to $38.79, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.

Referenced by the price of 1 transaction in Table I.

Read the full filing on SEC EDGAR (opens in a new tab)